This phase 3 trial of participants aged 6–11 years with cystic fibrosis showed that treatment with vanzacaftor–tezacaftor–deutivacaftor, a next-generation once-daily CFTR modulator regimen, was generally safe and well tolerated and resulted in further restoration of CFTR function from baseline treatment with elexacaftor–tezacaftor–ivacaftor. The gene discussed is CFTR; the disease is cystic fibrosis.